Greenwich LifeSciences, Inc. (GLSI) Dividend History

Greenwich LifeSciences, Inc. (GLSI) is a biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company specializes in advancing innovative treatments, including vaccines designed to stimulate the immune system against specific tumor-associated antigens. Its pipeline primarily targets breast and other solid tumors.

3992 Bluebonnet Dr, Building 14, Stafford, TX, 77477
Phone: 203-434-3290
Website:

Dividend History

Greenwich LifeSciences, Inc. currently does not pay dividends

Company News

  • Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

    Greenwich LifeSciences, a clinical-stage biopharmaceutical company, announced that its Board of Directors has extended the lock-up of shares owned by directors, officers, and existing pre-IPO investors to March 31, 2026. This move aims to restrict the sale of these shares during this period, unless otherwise modified by the Board.

    GlobeNewswire Inc.
  • Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

    Greenwich LifeSciences has activated clinical sites in Poland for its Phase III FLAMINGO-01 trial, which is evaluating an immunotherapy to prevent breast cancer recurrences. The trial is being led by Dr. Piotr Wysocki, a prominent oncologist in Poland, and will involve up to 150 sites globally.

    GlobeNewswire Inc.
  • Greenwich LifeSciences Provides Update on Commercial Manufacturing

    Greenwich LifeSciences, a clinical-stage biopharmaceutical company, has made substantial progress in the commercial manufacturing of GP2, an immunotherapy to prevent breast cancer recurrences. The company has manufactured the first three commercial lots of GP2 active ingredient and the first lot of GP2 vials, which can be used in the FLAMINGO-01 Phase III clinical trial or for commercial launch.

    GlobeNewswire Inc.
  • Greenwich LifeSciences Provides Update on Corporate Events

    Greenwich LifeSciences, a clinical-stage biopharmaceutical company, provided an update on its upcoming events, including conferences, a race sponsorship, and its Phase III clinical trial FLAMINGO-01 for its immunotherapy GLSI-100 to prevent breast cancer recurrences.

    GlobeNewswire Inc.
  • Greenwich LifeSciences Set to Join Russell 2000 Index Again

    STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list of additions updated as of June 21, 2024.

    GlobeNewswire Inc.
Dividend data last updated 06/08/2025 00:07:14 UTC